Brexucabtagene Autoleucel: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), NICE (England) and SMC (Scotland) recommended or restricted brexucabtagene autoleucel, while NYE METODER (Norway) did not recommend it.
Assessment has run over 5.2 years, from 24 Feb 2021 at NICE (England) to 27 May 2026 at ZIN (Netherlands).
ZIN (Netherlands) changed its position: not recommended on 9 Sep 2022, restricted by 27 May 2026, after a resubmission.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — HAS (France), PBAC (Australia) and PHARMAC (New Zealand) among them — hold no record for brexucabtagene autoleucel at all.
The file is active: 15 of 19 records date from 2023 or later.
Against its own class, brexucabtagene autoleucel is an outlier: 50% of its decisive outcomes were positive, where molecules sharing ATC class L01X average 75%.
4 distinct indication wordings are recorded for brexucabtagene autoleucel by the agencies that label one in English (AWMSG, NICE and SMC).
NICE (England) was first to assess brexucabtagene autoleucel, on 24 Feb 2021; DMC (Denmark) did not open a file until 21 Jan 2026 — a wide spread of 4.9 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 6 years in total.
6 of the 8 agencies here assessed brexucabtagene autoleucel more than once, CIPM (Spain) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for brexucabtagene autoleucel.
The full ledger for brexucabtagene autoleucel reads 9 not recommended, 5 recommended, 4 restricted and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 21 Jan 2026 | Voksne patienter på 26 år og derover med recidiveret eller refraktært B-celleprækursor akut lymfatisk leukæmi (ALL) | Anbefalet | source |
| AOTMIT (Poland) | 25 Jul 2025 | programu lekowego B.12.FM. Leczenie chorych na chłoniaki B-komórkowe (ICD-10: C82, C83, C85) Prezes Agencji rekomenduje … | recommended conditionally | source |
| ZIN (Netherlands) | 15 Jan 2025 | Advies - niet vergoeden brexucabtagene-autoleucel (Tecartus®) voor de behandeling van acute lymfoblastische leukemie | not reimbursed (sluis) | source |
| NYE METODER (Norway) | 22 Sep 2024 | Behandling av voksne med residivert eller refraktær mantelcellelymfom (MCL) etter to eller flere runder med systemisk be… | not introduced | source |
| CIPM (Spain) | 20 Mar 2024 | Indicacio nes terapéutica s autorizada s: Linfoma de células del manto Tecartus está indicado para el tratamiento de pac… | not financed by the SNS · art. 92 d, e | source |
14 further decisions for brexucabtagene autoleucel, across 8 agencies, are not shown here. They include the most recent record on file, 27 May 2026 from ZIN (Netherlands); its outcome is in the subscriber dataset. They link to 13 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 19 decisions for brexucabtagene autoleucel from 8 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.